Drugs / AZD9829
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06179511 | Jan 2024 → Oct 2025 | hematopoietic and lymphoid cell neoplasm | AstraZeneca | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AZD9829 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06179511 ↗ |
| Route | Intravenous | “AZD9829 will be administered by IV infusion” NCT06179511 ↗ |